Salix Pharmaceuticals is broadening its product line bypurchasing exclusive rights to four treatments from King Pharmaceuticals.

For $13 million in cash, Salix acquired two suppositories and two cream products for treatment of inflammation and other problems.

“We believe Anusol-HC and Proctocort can serve an important role in helping gastroenterologists and other physicians provide effective treatment of inflammatory and pruritic conditions,” said Ellen Marth McKim, vice president of marketing for Salix.

“Salix has the opportunity to grow the sales of these products based upon several key attributes, including the flexibility provided by the multiple dosage forms and strengths of the four products, and the fact that these products represent the only branded product line available in a suppository formulation for internal use supplemented by a cream formulation for external use.”